Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Here’s Why

Fresenius SE & Co. (OTCMKTS:FSNUY)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $12.72, but opened at $13.53. Fresenius SE & Co. shares last traded at $13.11, with a volume of 3,363 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Fresenius SE & Co. has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

The company has a market capitalization of $29.11 billion, a price-to-earnings ratio of 16.35 and a beta of 0.62. The business has a 50 day moving average price of $12.90 and a 200-day moving average price of $12.55. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.33% and a net margin of 6.67%.The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Research analysts predict that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care company headquartered in Bad Homburg. The company develops and provides products and services for hospitals, outpatient care, and patients with chronic or complex medical conditions.

Its principal operating businesses are Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies medicines, clinical nutrition products, infusion and transfusion technologies, and related devices and services. Fresenius Helios operates hospitals and outpatient facilities, primarily in Germany and Spain, providing a broad range of medical and surgical care.

Fresenius traces its origins to a pharmacy established by the Fresenius family in Frankfurt in the 15th century and has evolved into an international health care group serving markets across Europe, North America, Latin America, Asia, and other regions.